Analysts ponder soaring Arca shares

What's up at Arca Biopharma? Analysts have been scratching their heads trying to figure out why, after the developer announced a new patent on Friday--hardly earthshattering news--its stock would go up more than 200 percent. TheStreet's Adam Feuerstein suggests it could be the result of momentum trading, with a higher price building steam. Ironically, he adds, Arca disclosed that it still hasn't reached agreement with the FDA on its special protocol assessment for the new Phase III the agency demanded on bucindolol. And that's the kind of news that normally wouldn't excite investors. Report

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.